Patent intelligence · LT
LT 3254695
COMBINATION THERAPY INVOLVING ANTIBODIES AGAINST CLAUDIN 18.2 FOR TREATMENT OF CANCER
COMBINATION THERAPY INVOLVING ANTIBODIES AGAINST CLAUDIN 18.2 FOR TREATMENT OF CANCER
Patent details — LT 3254695
- Jurisdiction
- LT
- Status
- granted
- Grant date
- Dec 28, 2020
- Expiration
- Dec 23, 2040
- Applicant
- ASTELLAS PHARMA INC [JP]
- CPC classes
- A61K 33/ 243 A I, A61K 39/ 395 A I, A61K 45/ 06 A I, A61K/31337
Quick answer
LT 3254695 (COMBINATION THERAPY INVOLVING ANTIBODIES AGAINST CLAUDIN 18.2 FOR TREATMENT OF CANCER) is held by ASTELLAS PHARMA INC [JP]. Status: granted. Granted Dec 28, 2020. Expires Dec 23, 2040 (15 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- ASTELLAS PHARMA INC [JP]
- Grant date
- Expiration
- Claims
- —
- CPC classes
- A61K 33/ 243 A I, A61K 39/ 395 A I, A61K 45/ 06 A I, A61K/31337, A61K/314745, A61K/31513
More from ASTELLAS PHARMA INC [JP]
Related pharmaceutical patents in our USPTO index.
-
AU 2022206771
Drug conjugates comprising antibodies against Claudin 18.2
granted -
EP 3791896
KOMBINATIONSTHERAPIE MIT ANTIKÖRPERN GEGEN CLAUDIN 18.2 ZUR BEHANDLUNG VON KREBS
granted -
EP 3708579
CLAUDIN-6-SPEZIFISCHE IMMUNREZPTOREN UND T-ZELL-EPITOPE
granted -
HR P20200591
ANTIBODIES SPECIFIC FOR CLAUDIN 6 (CLDN6)
granted -
US 2020199221
ANTIBODIES USEFUL IN CANCER DIAGNOSIS
granted -
WO 2020095183
COMBINAISON POUR LE TRAITEMENT DU CANCER
granted -
US 2019076525
THERAPY INVOLVING ANTIBODIES AGAINST CLAUDIN 18.2 FOR TREATMENT OF CANCER
granted
Frequently asked questions
What is US patent 3254695?
LT 3254695 (COMBINATION THERAPY INVOLVING ANTIBODIES AGAINST CLAUDIN 18.2 FOR TREATMENT OF CANCER) is held by ASTELLAS PHARMA INC [JP]. Status: granted. Granted Dec 28, 2020. Expires Dec 23, 2040 (15 years remaining) — relevant for patent-cliff and LOE planning.
Who owns LT 3254695?
ASTELLAS PHARMA INC [JP] is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 25 pharmaceutical patents for this assignee.
When does LT 3254695 expire?
Our index shows an expiration date of Dec 23, 2040 (15 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.